Longterm Follow – up of cml Cases with Imatinib Induction: A Hematological and Cytogenetic based Report
Amit K. Dutta1, N. Ganesh1, C. S. Senthilkumar1 and N. K. Sah21Department of Research, Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal.
2School of Biotechnology, Rajiv Gandhi Technical University, Bhopal.
Abstract: Chronic Myeloid leukemia (CML) is a blood cancer of myeloid progenitors initiated with a triphasic absolutely curable with a targeted gene drug Imatinib mesylate. This study was conducted to reveal the effectiveness of Imatinib mesylate in 20 CML patients subjected with a follow – up of 9 months to evaluate their remission of the disease status. Complete hematological and Cytogenetic analysis was performed to find out the response of Imatinib mesylate against CML in every follow – up. Majority of the CML patients had showed a positive response in decreased level of abnormal cell proliferation and loss of Philadelphia positive chromosome(Ph+ve) in their profile. Our research evidenced a potential activity of Imatinib mesylate as a targeted gene therapy drug against CML.
Keywords: Chronic Myeloid Leukemia; Imatinib Induction; Long term follow – up studies Back to TOC